Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules

@article{Alesini2012MultimodalityTO,
  title={Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules},
  author={D. Alesini and R. Iacovelli and A. Palazzo and A. Altavilla and E. Risi and F. Urbano and C. Manai and A. Passaro and V. Magri and E. Cortesi},
  journal={Oncology},
  year={2012},
  volume={84},
  pages={92 - 99}
}
  • D. Alesini, R. Iacovelli, +7 authors E. Cortesi
  • Published 2012
  • Medicine
  • Oncology
  • Gynecomastia is a pathological enlargement of male breasts due to hormonal imbalance and elevation of estrogens at the expense of testosterone. It is very important to diagnose this disease precociously because it can be the expression of different underlying pathologies. Besides genetic, chromosomal or chronic diseases, drugs often represent the principal cause of this hormonal disequilibrium. In the elderly population, antiandrogen therapy for prostate cancer frequently induces gynecomastia… CONTINUE READING
    4 Citations
    Gynaecomastia—pathophysiology, diagnosis and treatment
    • 66
    • PDF
    EAA clinical practice guidelines—gynecomastia evaluation and management
    • 10

    References

    SHOWING 1-10 OF 39 REFERENCES
    Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
    • 95
    Gynecomastia in prepubertal and pubertal men
    • 57
    Drug-induced gynecomastia.
    • 11
    Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
    • 392